Research Management Committee. The goals and progress of the Research Program shall be determined and monitored by a Research Management Committee ("RMC"), which shall be composed of three members from each of Tularik and JT, the Chairperson of which shall be named by Tularik. A Party may replace any designee to the RMC by written notice to the other Party. The RMC shall meet at least twice annually at a time and place it so designates. The RMC will periodically review the Research Program and the Parties' progress thereunder, to the extent set forth in the Research Plan, including all screening results and new developments regarding the Field, and propose changes to the Research Plan based upon the results of prior work and new developments in the Field. The RMC will select the Collaboration Lead Compounds by a unanimous vote pursuant to Section 3(b). All data and information obtained by either Party pursuant to the Research Program will be provided to the RMC. The RMC will delegate responsibility for the filing and prosecution of Program Patents arising from the Research Program on inventions jointly discovered in the course of the Research Program Term. The RMC will be responsible for coordinating all aspects of all activities undertaken to identify and develop a Lead Compound that are necessary or desirable to determine whether such Lead Compound may be suitable for designation as a Collaboration Lead Compound pursuant to Section 3(b)(i). In addition, the RMC will be responsible for coordinating all aspects of all activities (including, but not limited to: [ * ] that will be undertaken with respect to a Collaboration Lead Compound that are necessary or desirable to enable the filing of an IND on Products based upon or incorporating such Collaboration Lead Compound, including the preparation and filing of an IND (collectively, "Pre-Clinical Development"). All decisions of the RMC shall be unanimous.
Research Management Committee. Warner and Onyx will each appoint up to 4 representatives to a research management committee (the “Research Management Committee”), which will oversee the operational aspects of performing the Research Plan. The Research Management Committee will assure that agendas and minutes are prepared for each of its meetings. The personnel, facilities, expertise and other resources of each party to be used in performance of the Research Plan shall be established by the Research Management Committee. The Research Management Committee will meet quarterly, or more frequently if mutually agreed. Warner’s and Onyx’s initial representatives to the Research Management Committee will be appointed by each of them promptly after the date of this Agreement. All actions taken and decisions made by the Research Management Committee shall be by unanimous agreement. A party may change any of its appointments to the Research Management Committee at any time upon giving written notice to the other party.
Research Management Committee. The Parties shall form a research management committee (the "RMC") comprised of four (4) individuals, two (2) being Rigel employees appointed and replaced by Rigel at its discretion, and two (2) being CG employees appointed and replaced by CG at its discretion. The size and composition of the RMC may be modified by mutual agreement of the Parties. The RMC shall evaluate the results of the Research set forth in the research reports pursuant to Section 3.4(a) to assess whether a peptide, protein or [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
Research Management Committee. 15 3.3 Drug Development Committee...................................... 16 3.4 Meetings........................................................ 17 3.5
Research Management Committee. Promptly after the Effective Date, ----------------------------- Warner and GenVec will each appoint three (3) representatives to a research management committee (the "Research Management Committee").
Research Management Committee. (a) To promote the success of the collaboration objectives and RNAi technology, the Parties will establish a Research Management Committee (“RMC”), which will be comprised of equal numbers of representatives of each of the Parties and will meet at least twice per calendar year, alternating venues between the vicinities of Cambridge, Massachusetts and Carlsbad, California, to share scientific direction and data, to coordinate basic research experiments, and to facilitate the guiding principles of the collaboration.
(b) Intellectual property representatives of each Party will be invited to participate in RMC meetings and such meetings will provide a forum to discuss patent prosecution and enforcement issues and to allocate responsibility for the filing and prosecution of any Joint Patents.
(c) Through the RMC, the Parties will update one another regarding the progress of the Research Program (as defined below), including a summary of the work each Party has performed thereunder; and regarding their respective Future Chemistry and Motif and Mechanism Patents.
(d) The RMC will establish a written clearance policy that will govern any publication or presentation by a Party in which such Party proposes to include any previously undisclosed information or intellectual property Controlled by the other Party.
(e) The RMC and any subcommittees and working groups established by the RMC will dissolve at the end of the Research Term. Upon termination of the RMC, the Parties will agree upon a strategy to make decisions about the items in Sections 4.1 (b), (c), and (d).
Research Management Committee. The Collaboration will be managed by the RMC, which will be comprised of three representatives appointed by SIGNAL and three representatives appointed by DPM. The RMC shall be co-chaired jointly by a representative of each party. Either party may appoint substitute or replacement members of the RMC to serve as their representatives upon notice to the other party. The initial members of the RMC shall be appointed by the parties within thirty (30) days following the Effective Date. The RMC shall oversee the principal research aspects of the Collaboration; and DPM shall be solely responsible for development, manufacturing and marketing activities. The RMC shall have the responsibility and authority to (a) set and modify research goals including recommendations to pursue different assays, (b) assign tasks and responsibilities under the Research Plan to the parties, (c) set criteria for identification of Lead Compounds and Hits, (d) recommend Hits to be developed as Lead Compounds and/or to be chemically modified for development as Lead Compounds, (e) monitor the progress of the Collaboration and (f) review and modify the Research Plan, as it shall deem appropriate to achieve the parties' objectives under this Agreement.
Research Management Committee. The design, review and conduct of the Research Program will be coordinated by the Research Management Committee, which will meet regularly on a mutually-agreeable schedule. The Research Management Committee may establish and amend or revise the Research Plan as necessary to reflect the scientific progress and work performed under the Research Program, such amendments to be mutually agreed to by ImClone and CombiChem. The Research Management Committee will consist of an equal number of members from ImClone and CombiChem and will include appropriate representatives from ImClone and CombiChem as mutually agreed. The co-chairs of the Research Management Committee will initially be the Vice President, Chemistry of CombiChem and the Vice President for Research of ImClone and subsequently may change as mutually-agreed upon by the Parties. Decisions of the Research Management Committee shall be by consensus. If a decision is not reached by the RMC with respect to management of the Research Program, the dispute will be referred to the co-chairs of the RMC. If the co-chairs of the RMC are unable to resolve the dispute, the dispute will be referred to the respective Chief Executive Officers of CombiChem and ImClone.
Research Management Committee. 2.2.1 Establishment and Functions of RMC. ----------------------------------
(a) DIVERSA and DOW hereby agree to establish the RMC. The RMC will act on behalf of the Parties and will be responsible for the planning and monitoring of the R&D Program and for setting forth specific research and development objectives, including, without limitation, (i) preparation and approval of each [*****] Plan in accordance with the procedures set forth in Appendix [*****] attached hereto and made a part hereof, (ii) determining whether research projects should be continued as active projects, and (iii) determining resource allocation for the R&D Program, so as to insure that meaningful research and development activity will be undertaken on all Research [*****] and Research [*****] in each [*****] period, taking into account that the overall research and development focus reflects both [*****] priorities.
(b) In planning and monitoring the R&D Program, the RMC shall assign tasks and responsibilities taking into account each Party's respective specific capabilities and expertise in order to avoid duplication and enhance efficiency and synergies. For example, [*****].
Research Management Committee. The design, review and conduct of the Research Program will be coordinated by the Research Management Committee, which will meet regularly on a mutually-agreeable schedule. Each Party shall bear its own expenses related to such meetings. The Research Management Committee may establish and amend or revise the Research Plan as reasonable and necessary to reflect the scientific progress and work performed under the Research Program, such amendments to be mutually agreed to in writing by Athena and CombiChem. The Research Management Committee will consist of an equal number of members from Athena and CombiChem and will include appropriate representatives from Athena and CombiChem as mutually agreed. The co-chairs of the Research Management Committee will initially be the Vice President, Chemistry of CombiChem and the Vice President, Research of Athena and subsequently may change as each Party determines for its co-chair. Decisions of the Research Management Committee shall be by consensus. If Athena elects not to file, maintain or prosecute such Patent, on a country-by-country basis, CombiChem shall have the right to take over such filing, maintenance or prosecution of such Patent, at its sole expense, and, as a result, CombiChem shall be entitled to recover from the proceeds of any infringement action brought by CombiChem in any such country (i) 200% of its out-of-pocket costs, and (ii) 50% of the balance of the proceeds of such action, with the remainder to be paid to Athena.
